Edition:
United Kingdom

Presbia PLC (LENS.OQ)

LENS.OQ on NASDAQ Stock Exchange Capital Market

2.23USD
19 Jun 2018
Change (% chg)

-- (--)
Prev Close
$2.23
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,386
52-wk High
$7.00
52-wk Low
$1.86

Summary

Name Age Since Current Position

Mark Yung

44 2017 Executive Chairman of the Board

Todd Cooper

50 2015 President, Chief Executive Officer, Director

Casey Lind

55 2018 Chief Operating Officer

Richard Fogarty

67 2018 Chief Accounting Officer, Vice President - Finance, Secretary

John Strobel

2015 Vice President of Sales

Magda Michna

42 2018 Chief Clinical Officer

Gerd Auffarth

2015 Director

Robert Cresci

73 2015 Director

Gerald Farrell

2016 Director

Zohar Loshitzer

57 2015 Director

Ressler Richard

56 2015 Director

Biographies

Name Description

Mark Yung

Mr. Mark T. Yung is Chairman of the Board of the Company. He is a co-founder and managing principal at OCV Management, LLC (“OCV”), an investment adviser based in Los Angeles California, which was co-founded by Mr. Yung and Richard Ressler, a member of our board and our majority stockholder, in 2016. Previously, Mr. Yung served as Managing Director at Orchard Capital Corporation (“Orchard Capital”), an investment firm affiliated with Mr. Ressler and located in Los Angeles, California, a firm he joined in 2006. Through his affiliation with OCV and Orchard Capital, Mr. Yung has and continues to serve in various senior capacities for companies in which OCV, Orchard Capital or their respective affiliates invest, including as Executive Chairman of Environmental Solutions Worldwide, Inc., as CFO and director of Polymer Plainfield Holdings, Inc., and as Chairman of Vantage Surgical Systems, Inc. Prior to Orchard Capital, Mr. Yung was a Senior Vice President in the Corporate Strategy and Merger and Acquisitions groups of Citigroup and ABN AMRO. Previously, Mr. Yung was an investment professional at JPMorgan Partners, where he focused on venture capital, growth equity and buyout transactions in Latin America and was a board member of various emerging companies. Mr. Yung is a Director of PacWest Bancorp, Inc. (NASDAQ: PACW). Mr. Yung holds a B.A. from Cornell University and an MBA from INSEAD. Neither Mr. Yung nor Mr. Loshitzer will be compensated directly by the Company for their services. Pursuant to the terms of a services agreement between the Company and OCV, the Company will pay OCV in shares of restricted stock, with an aggregate value of $250,000 per year. Contingent upon Messrs. Cooper and Thurman each executing a general release and waiver agreement (the “Release”) containing customary releases of claims, Messrs.

Todd Cooper

Mr. Todd Cooper is Chief Executive Officer, President, Director of Presbia Public Limited Company, since January 2015. From July 2011 to November 2014, Mr. Cooper served as the Chief Executive Officer of NVISION, which operates a network of ophthalmological surgical centers. From October 2008 to June 2010, Mr. Cooper served as the Vice President of Marketing and the General Manager of Henry Schein Medical, a division of Henry Schein, Inc., a global provider of health care products and services to office-based practitioners. Prior to that, Mr. Cooper served as: the Senior Vice President, Global Sales and Marketing of Discus, a global manufacturer of dental products (2003 to 2008); a Senior Vice President of IMG Holdings, (1997-2003); the Director of Marketing at The Franklin Mint, (1995 to 1997); and the Senior Marketing Manager at Canadian Tire Corporation, Limited, (1993 to 1995).

Casey Lind

Ms. Casey Jean Lind is Chief Operating Officer of the company. Prior to joining Presbia, from October 2017 to February 2018, Ms. Lind was the managing member of Pathfinder Global Way, LLC, a private consulting company. Prior to that, from 1998 to June 2017, Ms. Lind worked for Alcon, a Novartis (NYSE: NVS) company, where she held positions of increasing responsibilities, including leading the early Surgical Glaucoma and Drug Delivery R&D teams and most recently as a Project Head for the Retina group. Ms. Lind has numerous issued patents focused on drug delivery, injection control, MEMS based posterior segment drainage and flow, and manufacturing processes for phase transition drug formulations. Ms. Lind has an active role at both the national and local level in Ophthalmic World Leaders (OWL). She is an OWL Champion Member and contributes at the national level on the Executive Membership Committee, and locally, by actively planning and moderating Southern California OWL chapter meetings. Ms. Lind is a graduate of Iowa State University, with a degree in Business, and received her MBA from Webster University.

Richard Fogarty

Mr. Richard T. Fogarty serves as Chief Accounting Officer, Vice President - Finance, Secretary of Presbia Public Limited Company. Prior to rejoining Presbia, Mr. Fogarty provided contract professional services from August 2017 to October 2017 to Collectors Universe, Inc. (NASDAQ: CLCT) and from July 2016 to August 2017 to Identiv, Inc. (NASDAQ: INVE), respectively. From February 2014 to June 2016, Mr. Fogarty served as Presbia’s Chief Accounting Officer, Vice President of Finance and Secretary. He served as the Chief Accounting Officer of Presbia Holdings from August 2013 until its liquidation in 2015. Prior to Presbia, Mr. Fogarty served as Vice President Finance and Administration and CFO from February 2010 to August 2013 at Polymer Plainfield Precision, Inc., a provider of contract manufacturing services to the automotive and medical device industries. Mr. Fogarty held corporate controller and corporate finance positions in publicly-held companies Collectors Universe, Inc., which provides authentication and grading services for high-value collectibles, from March 2006 to February 2010, and Impco Technologies, Inc. (now Fuel Systems Solutions, Inc.), which designs, manufactures and supplies alternative fuel products and systems, from November 2002 to March 2006. Mr. Fogarty holds an M.B.A. from Fairleigh Dickinson University and a B.S. from Union College. Mr. Fogarty is a Certified Management Accountant.

John Strobel

Mr. John Strobel is Vice President of Sales of the Company. Mr. Strobel has extensive background in international sales and ophthalmology. He most recently served as Vice President of Sales and Marketing of Western Enterprises. Prior to that, Mr. Strobel served as Vice President of Sales and Marketing for Volk Optical, a diagnostic and surgical device manufacturer in the ophthalmology and optical markets. Over his 12 years at the firm, he built a global selling team in over 100 countries and drove 12 consecutive years of record revenues and increase in net profit as well as opening new offices and managing teams in India, China, Latin America, Europe, Middle East/Africa, and Australia. Earlier in his career, Mr. Strobel served in sales management roles at Hu-Friedy, a $100 million dental manufacturer and Depuy/Motech Spinal Systems. Mr. Strobel earned a Bachelor of Science in Biomedical Engineering from Tulane University and a Master of Business Administration in International Management from Thunderbird School of Global Management.

Magda Michna

Dr. Magda Michna is Chief Clinical Officer of the company. She joined Presbia as Vice President of Clinical Affairs in February 2017. Prior to joining Presbia, from October 2012 to February 2017, Dr. Michna lead clinical development for surgical products at Alcon, a Novartis (NYSE: NVS) company. Prior to Alcon, she worked in clinical research for Johnson and Johnson Vision Care, Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ). Her academic research was conducted at the McGill University School of Ophthalmology. Dr. Michna is a US representative on the ISO committee for ophthalmic implants.

Gerd Auffarth

Dr. Gerd Auffarth, M.D., Ph.D., is Director of the Company. Dr. Auffarth is Director of the International Vision Correction Research Centre (IVCRC) and The David J. Apple International Laboratory for Ophthalmic Pathology. Dr. Auffarth has his M.D. degree from RWTH Aachen Medical School, Aachen University of Technology in Germany. Dr. Auffarth’s core research is in cornea, corneal surgery, presbyopia, cataracts and intraocular lens implants. His expertise is in IOL’s, multi-focal IOL’s, refractive laser technologies and presbyopia surgery. Dr. Auffarth is considered a pioneer in Femtosecond laser surgery. In an article published by The Ophthalmologist Dr. Auffarth was ranked among the top 20 ophthalmologists in the world.

Robert Cresci

Mr. Robert J. Cresci is Director of Company. He has served as a director of Presbia PLC since March 2015. He has been a managing director of Pecks Management Partners Ltd., an investment management firm, since 1990. Mr. Cresci currently serves on the boards of j2 Global, Inc., Luminex Corporation, OFS Capital Corporation, CIM Commercial Trust Corporation, and several private companies. Mr. Cresci previously served on the board of Continucare Corporation until 2011 and the board of Sepracor, Inc. until 2009. By virtue of his time with Pecks Management Partners and the other business entities mentioned, Mr. Cresci brings to our board of directors his broad expertise and experience in accounting issues, and public company matters. Mr. Cresci holds an undergraduate degree in Engineering from the United States Military Academy at West Point and holds a M.B.A. in Finance from the Columbia University Graduate School of Business.

Gerald Farrell

Dr. Gerald Farrell, Ph.D., is Director of Presbia Public Limited Company. Dr. Farrell has been involved in the pharmaceutical industry for more than 25 years, and worked for Eli Lilly Company Limited in Ireland and the United Kingdom for the majority of his successful career. Dr. Farrell’s tenure at Eli Lilly included positions of Managing Director, leading the commercial sales and marketing in Ireland where he launched several major products in Europe; Director Strategy, Commercial and Business in the UK accountable for long-term strategic planning and business operations as well as other positions related to compliance, production, sales, and planning. Dr. Farrell earned a Ph.D. Plant Biotechnology from University College, Cork, and a BSc Honours – Plant Science and Higher Diploma Education with Honours from University College, Galway. Dr. Farrell serves on the Board for UCD Michael Smurfit Graduate Business School, serves as a director, and previously served as president, for Irish Pharmaceutical Healthcare Association, and serves as a council member for the Dublin Chamber of Commerce. Previously, from 2003 until 2014, Dr. Farrell served as a director of Eli Lilly and Company (Ireland) Ltd.

Zohar Loshitzer

Mr. Zohar Loshitzer is an Director of the Company., , effective September 30, 2015. he is no longer Chief Business Development Officer of Presbia Public Limited Company. He has served as the President and Chief Executive Officer and a director of Presbia Holdings since May 2007, served as the Chief Executive Officer of Presbia PLC from February 2014 to October 2014, served as the President of Presbia PLC from February 2014 to January 2015 and has served as a director of Presbia PLC since February 2014. Mr. Loshitzer assumed the position of Chief Business Development Officer of Presbia PLC upon Mr. Cooper’s election as the Chief Executive Officer and President of Presbia PLC in January 2015. Since January 2005, Mr. Loshitzer has served as a principal at Orchard Capital. he has served since August 2000 as the President and Chief Executive Officer of Universal Telecom Services, Inc. He has served as Executive Vice President of Corporate Strategy of j2 Global since June 2001 and from July 1997 through June 2001 he served as the Chief Information Officer at j2 Global. Mr. Loshitzer was the founder and President of MTP Consulting, Inc., from January 2011 to August 2013, and he was the founder and President of Imali, Inc., from January 2007 to December 2010. Since 1995, he has been a Managing Director at Orchard Telecom. He previously served as a consultant to MAI Systems Corporation, a provider of information technology solutions, and as a General Manager and Managing Director at Life Alert Emergency Response, Inc. which Mr. Loshitzer co-founded. He has been a director of the publicly-traded Advanced Cell Technology Inc. since December 2011 and publicly-traded Environmental Solutions Worldwide, Inc. since January 2011. He graduated from Tel Aviv University with a degree in Electronic Engineering.

Ressler Richard

Mr. Richard S. Ressler is a Director of Presbia Public Limited Company, since January 2015. He has served as an officer and a director of Presbia Holdings since May 2007 and commenced serving as a director of Presbia PLC in January 2015. Mr. Ressler serves on the board of Presbia Holdings pursuant to a services agreement between our company and Orchard Capital Corporation (“Orchard Capital”). Mr. Ressler is the founder, owner and President of Orchard Capital, (including Presbia). He has been President of Orchard Capital since 1994. Mr. Ressler has been Chairman of the Board of Directors of j2 Global, Inc. (“j2 Global”), since 1997, and served as j2 Global’s Chief Executive Officer from 1997 to 2000. Since March 2014, Mr. Ressler has been Chairman of the Board of Directors of CIM Commercial Trust Corporation. Through an agreement with Orchard Capital, Mr. Ressler serves in various senior capacities with, among other companies, CIM Group, L.P. (together with its affiliates, “CIM Group”) co-founded by Mr. Ressler, and Orchard First Source Asset Management (together with its affiliates, “OFSAM”) co-founded by Mr. Ressler. Both OFSAM and its wholly owned subsidiary, OFS Capital Management, LLC, are registered with the U.S. Securities and Exchange Commission as registered investment advisers. Mr. Ressler also serves as a board member for various private companies in which Orchard Capital or its affiliates invest. Mr. Ressler holds a B.A. from Brown University and J.D. and M.B.A. degrees from Columbia University.